Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 11, Pages 3030-3035
Publisher
Proceedings of the National Academy of Sciences
Online
2016-03-01
DOI
10.1073/pnas.1523693113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PTEN regulates lung endodermal morphogenesis through MEK/ERK pathway
- (2015) Yiming Xing et al. DEVELOPMENTAL BIOLOGY
- PTEN: Multiple Functions in Human Malignant Tumors
- (2015) Michele Milella et al. Frontiers in Oncology
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Conditional Reverse Tet-Transactivator Mouse Strains for the Efficient Induction of TRE-Regulated Transgenes in Mice
- (2014) Lukas E. Dow et al. PLoS One
- Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling
- (2014) M. Will et al. Cancer Discovery
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Genetically engineered mouse models of PI3K signaling in breast cancer
- (2013) Sjoerd Klarenbeek et al. Molecular Oncology
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
- (2013) A. B. Hanker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- (2013) H. Ebi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Life in the Fast Lane: Mammalian Disease Models in the Genomics Era
- (2012) Lukas E. Dow et al. CELL
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- A pipeline for the generation of shRNA transgenic mice
- (2012) Lukas E Dow et al. Nature Protocols
- Endogenous viruses: insights into viral evolution and impact on host biology
- (2012) Cédric Feschotte et al. NATURE REVIEWS GENETICS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference
- (2011) Prem K. Premsrirut et al. CELL
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
- (2010) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
- (2009) Babette Schade et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis
- (2008) N. Dourdin et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started